Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 oral azacitidine versus placebo in lower-risk myelodysplastic syndromes with transfusion-dependent anemia and thrombocytopenia
2012-002471-34Phase 3Completed
- Sponsor
- Celgene Corporation
- Start
- Oct 2012
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules, Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial in myelodysplastic syndrome (MDS) comparing Oral azacitidine plus best supportive care with Placebo plus best supportive care (2 arms). Primary endpoint: Red blood cell transfusion independence for at least 84 days. Started Oct 2012; status: completed.
02
Drugs
azacitidine
03
Conditions
myelodysplastic syndrome (MDS)
Beyond the preview
Go deeper on 2012-002471-34.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2012-002471-34.